QALSODY targets the root cause of SOD1-ALS, an ultra-rare and uniformly fatal neurodegenerative disease marked by motor neuron loss in the brain and spinal cord 1 Biogen's second rare disease therapy ...
QALSODY is the first therapy designed to address the underlying genetic cause of SOD1-ALS2, a rapidly progressive and uniformly fatal condition that impacts motor function, speech, and respiratory ...
HTA assessments highlight importance of timely and equitable access to QALSODY for this ultra-rare genetic form of ALS and urgent need for therapies that slow progression, preserve function and ...
The MarketWatch News Department was not involved in the creation of this content. -- CDA issues positive reimbursement recommendation for QALSODY -- INESSS recognizes QALSODY's promising clinical ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Neurofilament light chain and cerebrospinal fluid ...
Early initiation of tofersen (Qalsody) was associated with a numerically slower decline in people with SOD1 amyotrophic lateral sclerosis (ALS) compared with delayed treatment, according to data from ...
A British teenager with motor neurone disease has reportedly been denied access to a "miracle drug" which slows the decline caused by the condition. Lillia Jakeman, 19, was told about new drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results